Key result
Anti-inflammatory therapies, including colchicine, IL-1 antagonists, and interleukin-6 inhibitors, are reviewed for their evolving role in the management of atherosclerotic cardiovascular disease.
Why the study?
Recent neutral trials reignited controversy regarding colchicine efficacy and the need for alternative anti-inflammatory therapies, leaving questions about optimal management strategies.
This review provides an updated summary of anti-inflammatory therapies for ASCVD, addressing recent controversies and future directions.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Waksman et al. (2025) conducted a review in Atherosclerotic cardiovascular disease (ASCVD). Anti-inflammatory therapies (colchicine, IL-1 antagonists, interleukin-6 inhibitors) was evaluated. Anti-inflammatory therapies, including colchicine, IL-1 antagonists, and interleukin-6 inhibitors, are reviewed for their evolving role in the management of atherosclerotic cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: